Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). Although Src TK has been involved in such resistance, clinical development of its inhibitors has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Formisano, Luigi, D'Amato, Valentina, Servetto, Alberto, Brillante, Simona, Raimondo, Lucia, Di Mauro, Concetta, Marciano, Roberta, Orsini, Roberta Clara, Cosconati, Sandro, Randazzo, Antonio, Parsons, Sarah J., Montuori, Nunzia, Veneziani, Bianca Maria, De Placido, Sabino, Rosa, Roberta, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694888/
https://www.ncbi.nlm.nih.gov/pubmed/26325669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694888/
https://www.ncbi.nlm.nih.gov/pubmed/26325669

Ejemplares similares